HAMI 3379 is a potent and selective antagonist of the Cysteinyl leukotriene (CysLT2) receptor. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury. It also attenuates microglia-related inflammation.

HAMI 3379 shows very low potency on a recombinant CysLT1 receptor cell line (IC50>10000 nM). HAMI 3379 antagonizes leukotriene D4- (LTD4-) and leukotriene C4- (LTC4-) induced intracellular calcium mobilization (IC50: 3.8 nM and 4.4 nM, respectively), in a CysLT2 receptor reporter cell line[1].

HAMI 3379 (infused into the aortic cannula at a rate of 1% of the total flow rate; 0.01, 0.1, 1 μM; 20 min) concentration-dependently inhibits and reverses the LTC4-induced perfusion pressure increase and contractility decrease[1]. HAMI 3379 (ip; 0.025-0.4 mg/kg; 24 hours) decreases the acute brain injury 24 hours after middle cerebral artery occlusion (MCAO) with effective doses of 0.1-0.4 mg/kg and a therapeutic window of ～1 hour. It reduces neurological deficits and reduces infarct volume, brain edema, and neuronal loss and degeneration 24 and 72 hours after MCAO[2].